Elevated plasma concentrations of tumor necrosis factor receptor 1 (TNFR1) and tumor necrosis factor receptor 2 (TNFR2), two ADAM17 substrates, have been recently found to predict stage 3 chronic kidney disease (CKD) and ESRD in patients with type 1 and type 2 diabetes, respectively.13, 14. Here, TNFRSF1B is linked to type 2 diabetes mellitus.